The Society for Immunotherapy of Cancer (SITC) is pleased to announce the publication of a guideline update, “Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0” in the Journal for ImmunoTherapy of Cancer (JITC).
The RCC treatment landscape has evolved considerably since the previous publication of SITC’s RCC guideline in 2019. Immune checkpoint inhibitor (ICI) therapy is now approved in the adjuvant setting and is a treatment option for patients with resectable RCC at high risk for recurrence. Furthermore, additional ICI-based combination therapies have since been FDA-approved for advanced RCC. While these new approvals have increased the number of treatment options for patients, clinical utilization of ICIs is complex and requires careful consideration of disease- and patient-related characteristics.
The RCC Immunotherapy Guideline Expert Panel was formed to provide evidence- and consensus-based recommendations to assist clinicians with these complex clinical decisions. The guideline addresses important considerations related to topics such as treatment selection and sequencing, disease histology considerations, risk assessment, treatment of special patient populations with ICI therapy, response monitoring with ICI therapy, coordinated management of oligometastatic disease during or after ICI treatment, quality of life concerns, and immunotherapy education for patients and caregivers.
The guideline is now available in the JITC, SITC’s open access, peer-reviewed online journal.
Read more here.